The status of colorectal cancer care in the Netherlands: Past, present and future

European Journal of Health Economics

Volumn 10, Issue SUPPL. 1, 2009, Pages

  Schurer, Willemien ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

Colorectal cancer; Expenditure; Screening; The Netherlands; Treatment access

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

AGING; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER SCREENING; CANCER STATISTICS; CANCER THERAPY; COLORECTAL CANCER; CONFERENCE PAPER; DRUG COST; HEALTH CARE; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HEALTH INSURANCE; HUMAN; NETHERLANDS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 76649104009     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-009-0189-7     Document Type: Conference Paper

References (17)

1. Ministry of Health and Environment (Rijksinstituut voor Volksgezondheid en Mileu) (2008) Care balance: (Zorgbalans 2008). RIVM Report 260602003 (2008)
2. Ferlay, J., Autier, P., Boniol, M., et al.: Estimates of the cancer incidence and mortality in Europe in 2006. Annals Oncol. 18(3), 581-592 (2007) (Pubitemid 46359643)
3. Comprehensive Cancer Centres (VICK). Statistics Database (1989-2006). www.ikcnet.nl/page.php?id = 160. Accessed Aug 2009
4. Verdecchia, A., Francisci, S., Brenner, H., et al.: Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 8(9), 784-796 (2007) (Pubitemid 47321601)
5. National Population Health Atlas (Nationale Atlas Volksgzondheid). Version 3.16. www.rivm.nl/vtv/object-document/o4235n21143.html
6. Poos, M.J.J.C., Smit, J.M., Groetn, J., et al.: Health costs in the Netherlands 2005 (Kosten van ziekten in Nederland 2005. Zorg voor euro's-8). RIVM Report 27-751019. Bilthoven, The Netherlands (2008)
7. Polder, J.J., Takken, J., Meerding, W.J., et al.: Kosten van ziekten in Nederland. De zorgeuro ontrafeld. RIVM Report 270751005. Bilthoven, The Netherlands (2002)
8. van Rossum., L.G., van Rijn, A.F., Laheij, R.J., et al.: Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroentol. 135, 82-90 (2008)
9. Hol, L., van Leerdam, M.E., van Ballegooijen, M., et al.: Screening for colorectal cancer: Randomised trial comparing guaiac-based and immunoschemical faecal occult blood testing and flexible sigmoidoscopy. [Epub ahead of print] (2009)
10. Slobbe, L.C.J., Kommer, G.J., Smit, J.M., et al.: Kosten van ziekten in Nederland 2003. Zorg voor euro's-1. RIVM Report 270751010. Bilthoven, The Netherlands (2006)
11. Stichting Farmaceutische Kentegallen. Monitor dure geneesmiddelen 2004, 2005 en 2006
12. KWF Nederlandse Kankerbestrijding: Immigrants and cancer. Socio-cultural and epidemiological aspects. 90-71229-17-3, Oisterwijk (2006)
13. Damen, P.: Waiting list issues for patients with cancer. Information Providing Centre, Tilburg, The Netherlands (2006)
14. KWF Nederlandse Kankerbestrijding: Advice on waiting times in cancer care. March 2006. www.kwfkankerbestrijding.nl/index.jsp?objectid=kwfredactie: 6425
15. Foundation for Pharmaceutical Stastistics: Facts and Figures, August 2008. http://www.sfk.nl/algemeen/2008fandf
16. Nationale Zorgautoriteit: Beleidsregel CI-1087, dure geneesmiddelen (2009)
17. Oncoline: Landelijke werkgroep GastroIntestinal Tumoren. Coloncarcinoom (2008) http://www.oncoline.nl